71
AN APPROACH TO AN APPROACH TO PATIENT WITH PATIENT WITH BLEEDING DISORDER BLEEDING DISORDER Dr. Salma Afrose Associate Professor Department of Hematology

Approach to patients with bleeding disorders

Embed Size (px)

Citation preview

Page 1: Approach to patients with bleeding disorders

AN APPROACH TO AN APPROACH TO PATIENT WITH PATIENT WITH

BLEEDING BLEEDING DISORDERDISORDER

Dr. Salma AfroseAssociate ProfessorDepartment of Hematology

Page 2: Approach to patients with bleeding disorders

Haemostasis Definition

Spontaneous arrest of bleeding when a small vessel is cut or ruptured

Function • To prevent blood loss from intact vessel • Arrest of bleeding from injured vessel

Page 3: Approach to patients with bleeding disorders

Mechanism of Normal Haemostasis

Trauma

Vessel Constriction + Shed blood

Coagulation Platelet Adhesion & release of ADP

ThrombinFibrin Platelet aggregation

(unstable plug)

Stable Haemostatic Plug

Page 4: Approach to patients with bleeding disorders

Haemostatic system is a complex mosaic of activating inhibitory feedback or feed-forward pathways, integrating it’s 5 major components

Vessel Wall Vessel Wall Platelets Platelet Inhibitors Coagulation Fibrinolysis

Blood flow

Production of local Prevention of Haemostasis uncontrolled thrombosis

Page 5: Approach to patients with bleeding disorders
Page 6: Approach to patients with bleeding disorders

Damaged Endothelium

Role of Platelet in Haemostasis

vWF

1.Adhesion through vWF

2. Release of ADP, etc

3. Aggregation

4. Clot retraction

Platelet

Endothelial cell

Page 7: Approach to patients with bleeding disorders

FUNCTIONS OF vWF:

1. vWF mediates platelet adhesion at site of injury 2. Stabilizes FVIII in circulation

Page 8: Approach to patients with bleeding disorders

Pathways of Haemostasis

XII XIIa

XI XIa

IX IXa

VIIIa Ca2+Phospholipid

VII

Ca2+ Tissue factor

VIIa

X Xa

VIIIa, Ca2+, Phospholipid

Prothrombin (IIa)

Fibrinogen

Page 9: Approach to patients with bleeding disorders

Fibrinolytic Pathways Plasminogen

Intrinsic Extrinsic XIIa-pa u - pa

t - pa

PAI PAI

PlasminAP

Fibrin FDP

Page 10: Approach to patients with bleeding disorders

Protease action on Fibrinogen

& FibrinFIBRINOGEN PLASMIN Fibrinogen

degradation products

X,Y,D,E THROMBIN Fibrin monomer Fibrinopeptide A & B FIBRIN PLASMIN Fibrin

degradation[NON CROSS LINKED] products

X,Y,D,E

FACTOR XIII

FIBRIN PLASMIN D dimer[CROSS LINKED] X,Y,D,E

Page 11: Approach to patients with bleeding disorders

PRIMARY HYPER FIBRINOGENOLYSIS

BLOOD

FREE PLASMIN FIBRINOGEN FDP

ENDOGENOUS ACTIVATOR +PLASMINOGEN

FIBRINOGENOLYSIS

Page 12: Approach to patients with bleeding disorders
Page 13: Approach to patients with bleeding disorders

Clinical Distinction Between Disorders of Coagulation & Platelets or Vessel

Finding Disorder of Coagulation

Disorder of Platelets or

Vessels

Petechiae Rare Characteristic

Deep dissecting hematomas

Characteristic Rare

Superficial ecchymoses

Common usually large & solitary

Characteristic usually small & multiple

Hemarthrosis Characteristic Rare

Delayed Bleeding Common Rare

Page 14: Approach to patients with bleeding disorders

Clinical Distinction Between Disorders of Coagulation & Platelets or Vessel

FindingDisorder of Coagulation

Disorder of Platelets or

vesselBleeding from

superficial cuts & scratches

Minimal Persistent often profuse

Sex of patient80-90% of hereditary forms occur only in

Male

Relatively more common in females

Positive family history Common Rare

Page 15: Approach to patients with bleeding disorders

HAEMORRHAGIC DISORDER

Page 16: Approach to patients with bleeding disorders

Definition:These are a group of disorder of widely differing aetiology which have in common tendency to bleed due to defect in the mechanism of haemostasis.

Page 17: Approach to patients with bleeding disorders

Clinical Features:

1.Spontaneous bleeding in to the skin, mucous membranes & internal tissues.

2.Excessive or prolonged bleeding following trauma or surgery.

3.Bleeding from more than one site.

Page 18: Approach to patients with bleeding disorders

Classification: Due to Vascular Defects

• Acquired– Simple easy bruising – Senile purpura – Symptomatic vascular

purpura• Henoch-Scholein Purpura • Scurvy • Dysproteinaemia

– Miscellaneous – Orthostatic purpura – Mechanical purpura

• Congenital – Hereditary haemorrhagic

telangiectasia– Ehlar Danlos disease

Page 19: Approach to patients with bleeding disorders

ClassificationAbnormal Platelet Production • Acquired

– Idiopathic thrombocytopenic purpura

– Drugs & chemicals – Leukemias– Aplastic anaemia– Hypersplenism – Disseminated lupus

erythematosus– Dengue fever

Abnormal Platelet Production • Neonatal & Congenital

– Auto-immune – mothers with chronic ITP

– Drug administration to mother

Page 20: Approach to patients with bleeding disorders

Classification

• Congenital – Membrane receptor defects – Glanzmann’s Thrombasthenia– Enzyme defect – Phospholipase deficiency – Cycle-oxygenase deficiency – Granuels defects – Storage pool deficiency

• Acquired – Leukemias – Myelodysplasia– Myeloproliferative

disorders – Uraemia – DIC

Due to Disorder of Platelet Function

Page 21: Approach to patients with bleeding disorders

Classification

• Hereditary – X-linked recessive trait

• Haemophilia-A • Haemophilia-B

– Autosomal recessive trait• Afibrinogenemia• Factor XIII deficiency

– Autosomal Dominant trait • Von-Willbrand Disease

• Acquired – Haemorrhagic disease

of new born – Biliary obstruction – Malabsorption of Vitamin K– Drugs – Liver disease – DIC

Due to Disorder of Coagulation

Page 22: Approach to patients with bleeding disorders

THROMBOCYTOPENIA

Page 23: Approach to patients with bleeding disorders

Definition: Thrombocytopenia is defined as a reduction

in peripheral blood platelet count below the normal lower limit of 150 x 109/Liter .

There is no absolute relation between platelet count & occurrence & rate of bleeding.

Page 24: Approach to patients with bleeding disorders

Bleeding is common –<30000/L but not invariable<10000/L bleeding is usual & often severe

Thrombocytopenia is accompanied by positive tourniquet test & prolonged bleeding time.

Page 25: Approach to patients with bleeding disorders

Clinical Evaluation • History Purpuric

Coagulation disorder • Hereditary: Onset, positive family history• Acquired: Drug, Viral infection • Drug History• Family History• Clinical feature • Physical examination

Page 26: Approach to patients with bleeding disorders

Lab Investigation • Hemoglobin percentage • ESR • Total count & Differential count of WBC • Platelet count • Blood film – leukemia, platelet morphology• Bleeding time (BT)• Clotting time (CT)• Prothrombin time (PT)• Activated partial thromboplastin time (APTT)

Page 27: Approach to patients with bleeding disorders

Special Investigation • Platelet function test • Coagulation factor assay • Fibrinogen Degradation Product (FDP) • Fibrinogen assay • VWF

Page 28: Approach to patients with bleeding disorders

Immune Thrombocytopenic Purpura

Page 29: Approach to patients with bleeding disorders

Types of ITP• Primary (Idiopathic)• Secondary

Page 30: Approach to patients with bleeding disorders

Definition The term idiopathic thrombocytopenic purpura usually refers to thrombocytopenia in which apparent exogenous etiologic factors are lacking & in which diseases known to be associated with secondary thrombocytopenia have been excluded.

Page 31: Approach to patients with bleeding disorders

Classification

1. Acute Idiopathic Thrombocytopenic Purpura

2. Chronic Idiopathic Thrombocytopenic Purpura

Page 32: Approach to patients with bleeding disorders

Difference Between Acute & Chronic ITP

Feature Acute ITP Chronic ITPPeak of Age Children of 2-

6 years Adults 20-40 years

Sex predilection

None 3:1 female to male

Antecedent infection

Common 1-3 weeks before

Unusual

Onset of bleeding

Abrupt Insidious

Page 33: Approach to patients with bleeding disorders

Difference Between Acute & Chronic ITP

Feature Acute ITP Chronic ITP

Hemorrhagic bullae in mouth

Present in severe cases

Usually absent

Platelet count <20,000/ microL 30,000 – 80,000 / microL

Eosinophilia & lymphocytosis

Common Rare

Duration 2-6 weeks rarely longer

> 6 months

Spontaneous remissions

Occur in 80% cases

uncommon

Page 34: Approach to patients with bleeding disorders

Patho-physiology ITP is caused by platelet specific antibody that bind to patient’s own platelet which are then rapidly cleared from circulation by the mononuclear phagocytic system via macrophage Fc receptor.The auto antibodies formed against platelet gp-IIb/IIIa & gp-Ib/IX.Splenic sequestration account for the shortest survival of platelet in most patients but the liver & RE cells of the bone marrow can play a major role. The Spleen has also been implicated as site of antibody production.

Page 35: Approach to patients with bleeding disorders

PATHOGENESIS

PLATELET

PLASMA CELL

ANTIBODYCOATEDPLATELET MACROPHAGE

REMOVAL OF ANTIBODYCOATED PLATELETS

Page 36: Approach to patients with bleeding disorders
Page 37: Approach to patients with bleeding disorders
Page 38: Approach to patients with bleeding disorders

Clinical Features • Haemorrhagic manifestation of ITP are of

purpuric type• Severity of bleeding depends on platelet

count • Patient Usually present with cutaneous

purpura, petechiae, echymoses & easy bruising (dry purpura)

Page 39: Approach to patients with bleeding disorders

On Examination The outstanding feature is absence of physical findings other than those due to anemia:

• Anemia proportionate to the blood loss • Purpuric rashes • Splenomegaly in <10% cases

Page 40: Approach to patients with bleeding disorders

Lab Investigations: • Hemoglobin percentage – Reduced • CBC:

– WBC count normal / increased during bleeding episodes

–Platelet count reduced • Peripheral Blood film:

–Normocytic normochromic / microcytic anemia

–Platelets are morphologically abnormal; large, small & atypical forms

Page 41: Approach to patients with bleeding disorders

Lab Investigation• Bleeding time: Raised• Bone Marrow Examination: (in special

circumstances)– Megakaryocyte & their precurosors are

present in normal / increased number & shift to the left

– Other findings are normal – Sometime there is erythroid hyperplasia

if anemia is severe enough

Page 42: Approach to patients with bleeding disorders

• Special Cases: 1. Not responding to treatment or relapse 2. Patients above 60 years3. Before splenectomy

Page 43: Approach to patients with bleeding disorders

Diagnosis

• Bleeding manifestation without any physical sign except signs of hemorrhage

• Isolated thrombocytopenia

Page 44: Approach to patients with bleeding disorders

Differential Diagnosis

• Aplastic anemia• Acute leukemia• Drug induced thrombocytopenia

Page 45: Approach to patients with bleeding disorders

Treatment• Specific treatment

– Corticosteroid – Immunosuppressive therapy

o Azathioprineo Dexamethasoneo Methylprednisoloneo Ciclosporino Dapsoneo Vincristine

– Splenectomy

Page 46: Approach to patients with bleeding disorders

Treatment (Contd.)

• Supportive treatment – Blood transfusion– If emergency, platelet transfusion

Page 47: Approach to patients with bleeding disorders

Thrombotic Thrombocytopenic Purpura

It is a rare disease which is characterized by –– Fever – Thrombocytopenic purpura– Hemolytic anemia – Fluctuating neurological disturbances of

variable nature – Renal failure

It occurs in all age & have the Lab finding like HUS

Page 48: Approach to patients with bleeding disorders

Hemolytic Uremic Syndrome

Page 49: Approach to patients with bleeding disorders

DefinitionHemolytic uremic syndrome is a triad of microangiopathic hemolytic anameia, thrombocytopenia & acute renal insufficiency.

Page 50: Approach to patients with bleeding disorders

Aetiology E.coli 0156:H7 Shigella dysentery serotype-I

(less frequently)

Types

Page 51: Approach to patients with bleeding disorders

PathogenesisToxin Absorption from Gut in to blood

Attachment to the receptor membrane

Endocytosed Cytolysis Endothelial swelling & desquamation

Platelet & Coagulation activation

Page 52: Approach to patients with bleeding disorders

Symptoms• Bloody diarrhoea• Severe abdominal pain• Vomiting• Passage of dark red urine which may lead

to Oliguria or anuria

Page 53: Approach to patients with bleeding disorders

Signs• Anemia • Jaundice • Bleeding manifestation

Page 54: Approach to patients with bleeding disorders

Lab Findings • Hemoglobin – Decreased• Platelet count – Decreased • Peripheral Blood film - Evidence of hemolysis

present• Serum bilirubin – Increased• Blood urea – Increased• Hemoglobinaemia - Present • Hemoglobinurea – Present• Stool Culture

Page 55: Approach to patients with bleeding disorders

Treatment• Fluid & electrolyte balance• Dialysis if required • Medication, such as anti-biotic if

indicated • Blood / blood product transfusion if

necessary

Page 56: Approach to patients with bleeding disorders

Clinical Features • Patient may present with mucosal

bleeding –Epistaxis–Haematuria –Menorrhagia–Melaena

• Intracranial Haemorrhage (rare)

Page 57: Approach to patients with bleeding disorders

Hemophilia

Page 58: Approach to patients with bleeding disorders

DefinitionIt is an inherited & X-linked recessive disease

Classification Haemophilia A – Factor VIII

deficiency Haemophilia B – Factor IX deficiency

Page 59: Approach to patients with bleeding disorders

The daughters of affected males are obligate carriers but the sons are normal.

Page 60: Approach to patients with bleeding disorders

Clinical FeaturesBleeding tendency usually appear in

infancy In mild cases it may not become

apparent until adolescent or adult life Coagulation factor <1% is severe Coagulation factor 1-5% is moderate Coagulation factor 6-40% is mild

Page 61: Approach to patients with bleeding disorders

Clinical Feature (contd.) Hemarthrosis Bleeding from skin Tissue bleeding EpistaxisBleeding from central nervous systemUrogenic & gastro-intestinal bleeding

Page 62: Approach to patients with bleeding disorders

Signs

Anemia Chronic arthritic changes in joints Haematoma

Page 63: Approach to patients with bleeding disorders

Diagnosis History

Age Sex

History of maternal side Physical findings Clinical findings

Page 64: Approach to patients with bleeding disorders

InvestigationBleeding time – Normal Platelet count – NormalClotting time – Raised Prothrombin time – Normal APTT – Raised Factor VIII / IX assay - Deficient

Page 65: Approach to patients with bleeding disorders

Management General Supportive treatment

Rest Local haemostatic measure Replacement therapy

FFP Factor VIII or IX concentrate Blood transfusion

Fibrinolytic inhibitors Aminocapric acid Tranexamic acid

Page 66: Approach to patients with bleeding disorders

Disseminated Intravascular Coagulation

Page 67: Approach to patients with bleeding disorders

Definition DIC is an acquired syndrome occurs as a result of inappropriate & excessive activation of haemostatic system that leads to the formation of micro-thrombi throughout the circulation of the body & consumption of platelet, fibrin & coagulation factors

Page 68: Approach to patients with bleeding disorders

Investigations CBC – Bleeding Time - Raised Platelet Count – DecreasedProthrombin Time – Raised APTT – Raised Fibrinogen Level – Reduced Fibrin Degradation Product – Raised Blood film -

Page 69: Approach to patients with bleeding disorders

PERIPHERAL BLOOD SMEAR IN DIC

MICROSPHEROCYTE

SCHISTOCYTE

Page 70: Approach to patients with bleeding disorders

Treatment Treatment of the cause Replacement of coagulation factors &

plateletAnti-coagulant therapy

Page 71: Approach to patients with bleeding disorders